Pandorum Technologies, a biotechnology firm specialising in programmable regenerative medicine, has raised USD 18 million in a Series B funding round to accelerate clinical development and broaden global access to its disease-modifying therapies.
The funding round was led by Protons Corporate, with investments from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, the Burman Family and other strategic backers. The transaction was advised by Bandana Kankani, advisor and investor at Pandorum, who helped structure the round in line with the company’s long-term growth and value creation plans.
Co-founded by Dr Tuhin Bhowmick and Arun Chandru, Pandorum operates in India and the United States. The company has developed a proprietary technology platform that combines biological science, engineering and computational tools to create regenerative, exosome-based therapies. These therapies aim to reprogram diseased tissues affected by conditions such as inflammation and fibrosis, enabling functional restoration.
Commenting on the fundraise, Dr. Bhowmick said the investment would support the translation of advanced scientific research into programmable therapies with disease-modifying potential. He added that the company intends to scale from single-tissue treatments to multi-tissue regenerative solutions, aligned with its long-term vision for healthy ageing.
Arun Chandru emphasised the global relevance of regenerative medicine, particularly in addressing unmet medical needs such as corneal blindness across diverse regions.
Pandorum’s clinical development efforts are supported by internationally recognised medical experts, including Dr Virender Singh Sangwan of Dr Shroff’s Charity Eye Hospital, New Delhi; Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine; and Dr Ramez Haddadin and Dr Satish Nadig from Northwestern Medicine, Chicago.
For global commercial expansion, the company is implementing a distributed manufacturing model. This includes a contract development and manufacturing partnership with AGC Biologics in Italy for the US and European markets, as well as a strategic collaboration with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to serve the Asia-Pacific region. The company is also evaluating manufacturing and commercial partnerships in the Middle East.
Pandorum’s lead product candidate, Kuragenx, is being developed for ocular surface disorders such as Stevens Johnson Syndrome and Neurotrophic Keratitis and has received Orphan Drug Designation from the US Food and Drug Administration. In addition to ophthalmology, the company is extending its regenerative platform to address inflammatory and degenerative conditions affecting the lungs, liver and nervous system.